Factors Associated with Mortality Among Patients with Drug-Resistant Pulmonary Tuberculosis in Sumatera, Indonesia, 2020–2024

Authors

  • Fajriani Dwi Wahyuni Epidemiology Study Program, Universitas Andalas, Padang, West Sumatera, Indonesia Author
  • Ratno Widoyo Epidemiology Study Program, Universitas Andalas, Padang, West Sumatera, Indonesia Author
  • Syafrawati Syafrawati Epidemiology Study Program, Universitas Andalas, Padang, West Sumatera, Indonesia Author

DOI:

https://doi.org/10.22437/jkmj.v10i1.55369

Keywords:

Drug-resistant tuberculosis, Mortality, Risk factors, Retrospective cohort, Indonesia

Abstract

Drug-resistant tuberculosis (DR-TB) remains a major public health problem due to its high mortality and low treatment success rates. Sumatra is one of the regions in Indonesia with a high burden of DR-TB mortality. This study aimed to analyze factors associated with mortality among patients with drug-resistant pulmonary tuberculosis in Sumatra during 2020–2024. This study used a quantitative analytical observational design with a retrospective cohort approach utilizing secondary data from the Tuberculosis Information System (SITB) of the Ministry of Health of Indonesia. A total sampling technique was applied to all eligible DR-TB patients. The dependent variable was mortality during treatment, while independent variables included age, sex, employment status, HIV status, type of health facility, residential area, and treatment history. Data were analyzed using univariate, bivariable, and multivariable analyses. Multivariable analysis was performed to identify factors associated with mortality after adjustment for confounding factors. The results showed that age and treatment history were significantly associated with mortality (p<0.05). Patients aged ≥45 years had a 1.60 times higher risk of death compared to younger patients, while previously treated patients had a 1.32 times higher risk of mortality compared to new cases. Other variables were not significantly associated with mortality. These findings highlight the importance of closer monitoring among older and previously treated DR-TB patients.

References

1. World Health Organization (WHO). Tuberculosis [Internet]. WHO Website. 2024 [cited 2024 Nov 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis

2. Di K, Bengkulu K. Analysis of the Economic Burden and the Impact of Tuberculosis on Community Welfare in Bengkulu City. (Analisis Beban Ekonomi Dan Dampak Karena Tuberculosis Terhadap Kesejateraan Di Kota Bengkulu). CHMK Heal J. 2020;4.

3. Perhimpunan Dokter Paru Indonesia. Tuberculosis: Guidelines for Diagnosis and Management in Indonesia (Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia). Vol. 001, Perhimpunan Dokter Paru Indonesia. 2021. 1–78 p.

4. Ministry of Health of the Republic of Indonesia. Technical Guidelines for the Management of Drug-Resistant Tuberculosis in Indonesia. (Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan. Petunjuk teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia). In 2020. p. 218.

5. Mirzayev F, Viney K, Linh NN, Gonzalez-angulo L, Gegia M, Jaramillo E, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update Fuad. Cross Mark [Internet]. 2021; Available from: http://dx.doi.org/10.1183/13993003.03300-2020

6. World Health Organization (WHO). Global tuberculosis report 2024. 2024.

7. World Health Organization (WHO). Tuberculosis in South-East Asia Region [Internet]. WHO Website. 2024 [cited 2025 Mar 1]. Available from: https://www.who.int/southeastasia/health-topics/tuberculosis

8. Zulfa Ayuningsih TYMW. Factors Associated with Mortality Among Patients with Multidrug-Resistant Tuberculosis During Treatment in Indonesia, 2015–2017. (Faktor yang Berhubungan dengan Kematian Pasien TB MDR Selama Masa Pengobatan di Indonesia Tahun 2015-2017). Pro Heal J Ilm Kesehat. 2019;1(2):1–46.

9. Chung-delgado K, Guillen-bravo S, Revilla-montag A, Bernabe-ortiz A. Mortality among MDR-TB Cases : Comparison with Drug-Susceptible Tuberculosis and Associated Factors. PLoS One [Internet]. 2015;1–10. Available from: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0119332&type=printable

10. Province S, Mutembo S, Mutanga JN, Musokotwane K, Kanene C, Dobbin K, et al. Urban-rural disparities in treatment outcomes among recurrent TB cases in Southern Province, Zambia. BMC Infect Dis. 2019;1–8.

11. Adamu AL, Aliyu MH, Galadanci NA, Musa BM, Lawan UM, Bashir U, et al. The impact of rural residence and HIV infection on poor tuberculosis treatment outcomes in a large urban hospital : a retrospective cohort analysis. Int J Equity Health. 2018;1–11.

12. Loprang MR, Ronoatmodjo S. Analysis of HIV Status as a Factor Associated with Increased Mortality Risk Among Patients with Drug-Resistant Tuberculosis Receiving Short-Term Treatment in Indonesia, 2020–2022. (Analisa Status HIV sebagai salah satu faktor yang meningkatkan risiko kematian pada pasien TBC RO dengan pengobatan jangka pendek di Indonesia tahun 2020- 2022). COMSERVA J Penelit dan Pengabdi Masy. 2025;4(9):3136–44.

13. Nasution HS, Yunis T, Wahyono M. Factors Associated with Loss to Follow-Up Among Patients with MDR/RR Tuberculosis in DKI Jakarta, 2014–2015. (Faktor-Faktor yang Mempengaruhi Kejadian Putus Berobat pada Kasus TB MDR/RR di DKI Jakarta tahun 2014-2015). J Kesmas Jambi. 2020;4(2):50–8.

14. Asokan S. Immune issues in elderly with TB. Indian J Tuberc [Internet]. 2022;69:S241–5. Available from: https://www.sciencedirect.com/science/article/pii/S001957072200141X

15. Olmo-font M. Tuberculosis in an Aging World. MDPI. 2022;1–13.

16. Bello S, Afolabi RF, Ajayi DT, Sharma T, Owoeye DO, Oduyoye O, et al. Empirical evidence of delays in diagnosis and treatment of pulmonary tuberculosis : systematic review and meta-regression analysis. BMC Public Health. 2019;1–11.

17. Kuo A, Teo J, Singh SR, Prem K, Hsu LY, Yi S. Duration and determinants of delayed tuberculosis diagnosis and treatment in high ‑ burden countries : a mixed ‑ methods systematic review and meta ‑ analysis. Respir Res [Internet]. 2021; Available from: https://doi.org/10.1186/s12931-021-01841-6

18. Tegegne BS, Mengesha MM, Teferra AA, Awoke MA. Association between diabetes mellitus and multi-drug-resistant tuberculosis : evidence from a systematic review and meta-analysis. BMC. 2018;7(161).

19. Teramaj Wongel Wotale, Abiyot Negash Terefe JAF. Modeling Time to Death of Patients with Multidrug-Resistant Tuberculosis at Saint Peter’s Specialized Hospital. J Res Health Sci. 2021;21(2).

20. Muluneh MA, Zeru AB, Derseh BT, Kebede AM. Survival Status and Predictors of Mortality among Multidrug-Resistant Tuberculosis Patients in Saint Peter ’ s Specialized Hospital , Addis Ababa , Ethiopia. Can J Infect Dis Med Microbiol. 2021;2021.

21. Tola H, Mansournia MA. National treatment outcome and predictors of death and treatment failure in multidrug- ­ resistant tuberculosis in Ethiopia : a 10- ­ year retrospective cohort study. BMJ Open. 2021;1–9.

22. Kassie G, Gezahegn E, Endazenawe G, Shitemaw T, Negash Z, Dessu S. Survival status and risk factors for mortality among multidrug-resistant tuberculosis patients in Addis Ababa , Ethiopia : A retrospective follow-up study. J Clin Tuberc Other Mycobact Dis [Internet]. 2023;33(September):100398. Available from: https://doi.org/10.1016/j.jctube.2023.100398

23. Ault R, Dwivedi V, Koivisto E, Nagy J, Miller K, Nagendran K, et al. Altered monocyte phenotypes but not impaired peripheral T cell immunity may explain susceptibility of the elderly to develop tuberculosis. Exp Gerontol [Internet]. 2018;111:35–44. Available from: https://www.sciencedirect.com/science/article/pii/S0531556518302870

24. Piergallini TJ, Turner J, Antonio S. Tuberculosis in the elderly: Why inflammation matters. HHS Public Access. 2019;32–9.

25. Mrema G, Hussein A, Magoge W, Mmbaga V, Balama R, Nkiligi E. Predictors of mortality among multidrug ‑ resistant tuberculosis patients after decentralization of services in Tanzania from 2017 to 2019 : retrospective cohort study [Internet]. Bulletin of the National Research Centre. Springer Berlin Heidelberg; 2024. Available from: https://doi.org/10.1186/s42269-024-01235-w

26. Atif M, Bashir A, Ahmad N, Fatima RK, Saba S, Scahill S. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients. BMC Infect Dis. 2017;1–12.

27. Ayuningsih Z, Yunis T, Wahyono M. Faktor yang Berhubungan dengan Kematian Pasien TB MDR Selama Masa Pengobatan di Indonesia Tahun 2015-2017. Pro Heal J Ilm Kesehat. 2019;1(2):41–7.

28. Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis – a systematic review. BMC Public Health. 2008;12.

29. Hargreaves JR, Boccia D, Evans CA, Adato M, Petticrew M. The Social Determinants of Tuberculosis : From Evidence to Action. Fram Heal Matters. 2011;101(4):654–62.

30. CDC. Tuberculosis (TB) [Internet]. CDC Website. 2025 [cited 2026 Apr 1]. Available from: https://www.cdc.gov/tb/health-equity/index.html

31. Ali HML, Elfiyunai NN, Suryawanto N, Siauta VA. Association Between Social Support and Treatment Adherence Among Tuberculosis Patients in the Service Area of UUPTD Banggai Community Health Center. (Hubungan Sosial Support terhadap Kepatuhan Pengobatan Pasien TB di Wilayah Kerja UPTD Puskesmas Banggai. J Pendidik Tambusai) [Internet]. 2023 Nov 28;7(3 SE-Articles of Research):26870–7. Available from: https://jptam.org/index.php/jptam/article/view/10961

32. Ismah Z, Sintia A, Nurjanah D, Sri M, Dalimunthe R. Association Between High-Risk Occupations and Tuberculosis Infection: Analysis of Patient Data at the North Sumatra Provincial Special Pulmonary Hospital, 2020–August 2024. (Hubungan Pekerjaan yang Beresiko Terinfeksi TB: Analisis Data Pasien di UPTD RS Khusus Paru Pemprovsu 2020–Agustus 2024). PREPOTIF J Kesehat Masy. 2024;8(3):6905–14.

33. Zheng Z, Nehl EJ, Zhou C, Li J, Xie Z, Zhou Z, et al. Insufficient tuberculosis treatment leads to earlier and higher mortality in individuals co-infected with HIV in southern China : a cohort study. BMC Infect Dis. 2020;1–10.

34. Lelisho ME, Wotale TW, Tareke SA, Alemu BD, Hassen SS, Yemane DM. Survival rate and predictors of mortality among TB / HIV co ‑ infected adult patients : retrospective cohort study. Sci Rep [Internet]. 2022;1–11. Available from: https://doi.org/10.1038/s41598-022-23316-4

35. Yusria A, Rintiswati N, Sumardi. Factors Associated With Tuberculosis Treatment Success Among Human Immunodeficiency Virus - Tuberkulosis (Hiv-Tb) in H. Adam Malik General Hospital, Medan. Trop Med J. 2018;4(1):16–24.

36. World Health Organization (WHO). WHO consolidated guidelines on tuberculosis Module 4: Treatment. WHO Web; 2022. 60 p.

37. World Health Organization (WHO). Tuberculosis Care TREATMENT Endorsements : WHO Web; 2025. 60 p.

38. World Health Organization (WHO). Public-Private Mix For TB Preventation And Care A Roadmap [Internet]. WHO Web; 2020. 36 p. Available from: https://iris.who.int/server/api/core/bitstreams/d5facafd-b1b8-4b04-9759-2a0511d23069/content

39. Health W, Regional O. Rural poverty and health systems in the WHO European Region [Internet]. Available from: https://www.who.int/activities/addressing-health-inequities-among-people-living-in-rural-and-remote-areas

40. Yuwono A, Id S, Nurhayati RD, Purwiga A, Lestari W, Pratiwi C, et al. Factors associated with treatment outcome of MDR / RR-TB patients treated with shorter injectable based regimen in West Java Indonesia. PLoS One [Internet]. 2022;72. Available from: http://dx.doi.org/10.1371/journal.pone.0263304

41. Ria Rizky, Helmi Surani Nasution, Ashar Nuzulul Putra MBB. Factors of Treatment Success Among Patients with Rifampicin-Resistant Tuberculosis (RR-TB) in Jambi Province. (Faktor-Faktor Keberhasilan Pengobatan Pasien Tuberkulosis Resisten Rifampisin (TB-RR) di Provinsi Jambi). J Penelit Kesmasy. 2026;8(2):225–35.

42. World Health Organization (WHO). Global Tuberculosis Report 2021 [Internet]. WHO Web; 2021. 57 p. Available from: https://www.who.int/publications/i/item/9789240037021

Downloads

Published

2026-03-31

Issue

Vol. 10 No. 1 (2026): VOLUME 10 - NUMBER 1 - March 2026

Section

Articles

License

Copyright (c) 2026 Fajriani Dwi Wahyuni, Ratno Widoyo, Syafrawati Syafrawati (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Proposed Creative Commons Copyright Notices

1. Proposed Policy for Journals That Offer Open Access
Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).




Proposed Policy for Journals That Offer Delayed Open Access


Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication, with the work [SPECIFY PERIOD OF TIME] after publication simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

 

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

 

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Most read articles by the same author(s)